Actively Recruiting
Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer
Led by Sun Yat-sen University · Updated on 2026-01-13
104
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to explore whether androgen deprivation therapy combined with novel androgen receptor inhibitors, prostate cryoablation, and metronomic cyclophosphamide is superior to the current treatment regimen of androgen deprivation therapy plus novel androgen receptor inhibitors for patients with metastatic prostate cancer. It will also learn about the safety of prostate cryoablation, and metronomic cyclophosphamide for patients with metastatic prostate cancer. The main questions it aims to answer are: Does prostate cryoablation, and metronomic cyclophosphamide delay the progression of metastatic prostate cancer? Does prostate cryoablation, and metronomic cyclophosphamide reduce symptomatic local events of metastatic prostate cancer? Researchers will explore if androgen deprivation therapy combined with novel androgen receptor inhibitors, prostate cryoablation, and metronomic cyclophosphamide works to treat metastatic prostate cancer. Participants will: Receive treatment of androgen deprivation therapy and novel androgen receptor inhibitors until progression. Receive prostate cryoablation surgery and take cyclophosphamide. Visit the clinic every 1-3 months for checkups and tests. Keep a diary of their symptoms.
CONDITIONS
Official Title
Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male between 18 and 80 years old
- Confirmed diagnosis of prostatic acinar adenocarcinoma
- Diagnosed with metastatic prostate cancer at initial diagnosis per AJCC 8th edition
- No cancer progression when starting prostate cryoablation
- ECOG performance status of 0 or 1
- Able to tolerate general anesthesia and prostate cryoablation surgery
- No significant medical abnormalities
- Able to understand the study and sign informed consent
You will not qualify if you...
- Serious illness making treatment unsafe
- Other cancers within past 5 years except non-melanoma skin cancer
- Prior treatments other than this study's regimen
- Prostate cancer invading the rectum
- Prostate volume greater than 55 ml after 6 months of androgen deprivation therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510062
Actively Recruiting
Research Team
Z
Zhenyu Yang, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here